Grant: Project Grant - PA: Breast Cancer Research
McGill University
$100,000.00
Engineering injectable cold atmospheric plasma-preserved hydrogel to treat breast cancer
EF 2021-22
Résumé
Immune checkpoint blockade (ICB) therapy is an emerging cancer therapy that reactivates the immune system and has greatly transformed the landscape of human cancer therapeutics. ICB uses immune checkpoint inhibitors (ICIs) to block negative immune regulators so that anti-tumor immune systems are strengthened to fight cancer. Several ICIs have been approved for treating solid multiple cancers and have shown encouraging outcomes in some cancer patients. However, challenges associated with ICB still exist, including low response rates in patients and severe side effects. Therefore, engineering strategies to address these unmet clinical challenges to improve impact of current and future immunotherapies are highly needed.
We will engineer a novel injectable therapeutic hydrogel, namely cold atmospheric plasma (CAP)-preserved hydrogel, to deliver ICIs for enhanced ICB therapy with minimized side effects. CAP, a unique type of ionized gas that is preserved in gels, can augment efficacy of ICB therapy. Injectable gels offer local and sustainable drug release to reduce systemic toxicities associated with ICB. We will investigate this strategy for treating triple negative breast cancer (TNBC), an aggressive type of breast cancer that has a high mortality rate among breast cancer patients. While ICB shows some positive effects in a small number of TNBC patients, the overall efficacy requires improvement and unwanted side effects need to be eliminated.
In summary, we aim to engineer an injectable hydrogel containing both CAP and ICI to treat TNBC. We will investigate the engineered gels in treating primary TNBC and metastatic TNBC. We will also evaluate the engineered gels in preventing tumor relapse.
We anticipate that this treatment strategy can be easily modified and further extended to treat other solid cancers, advancing research and translation of biomaterials-mediated cancer immunotherapies, which could ultimately bring immense clinical benefits for cancer patients.
Programme
Project Grant - PA: Breast Cancer Research
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
455833
Name
Chen Guojun
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Biomedical Engineering
Projecttitle
Engineering injectable cold atmospheric plasma-preserved hydrogel to treat breast cancer
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Breast Cancer Research
Keyworddelim
Biomaterials; Cold Atmospheric Plasma; Combined Therapy; Drug Delivery; Hydrogel; Immune Checkpoint Blockade; Triple Negative Breast Cancer
Abstract
Immune checkpoint blockade (ICB) therapy is an emerging cancer therapy that reactivates the immune system and has greatly transformed the landscape of human cancer therapeutics. ICB uses immune checkpoint inhibitors (ICIs) to block negative immune regulators so that anti-tumor immune systems are strengthened to fight cancer. Several ICIs have been approved for treating solid multiple cancers and have shown encouraging outcomes in some cancer patients. However, challenges associated with ICB still exist, including low response rates in patients and severe side effects. Therefore, engineering strategies to address these unmet clinical challenges to improve impact of current and future immunotherapies are highly needed.
We will engineer a novel injectable therapeutic hydrogel, namely cold atmospheric plasma (CAP)-preserved hydrogel, to deliver ICIs for enhanced ICB therapy with minimized side effects. CAP, a unique type of ionized gas that is preserved in gels, can augment efficacy of ICB therapy. Injectable gels offer local and sustainable drug release to reduce systemic toxicities associated with ICB. We will investigate this strategy for treating triple negative breast cancer (TNBC), an aggressive type of breast cancer that has a high mortality rate among breast cancer patients. While ICB shows some positive effects in a small number of TNBC patients, the overall efficacy requires improvement and unwanted side effects need to be eliminated.
In summary, we aim to engineer an injectable hydrogel containing both CAP and ICI to treat TNBC. We will investigate the engineered gels in treating primary TNBC and metastatic TNBC. We will also evaluate the engineered gels in preventing tumor relapse.
We anticipate that this treatment strategy can be easily modified and further extended to treat other solid cancers, advancing research and translation of biomaterials-mediated cancer immunotherapies, which could ultimately bring immense clinical benefits for cancer patients.
Competitiondate
202109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chen, Guojun
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~